Filing Flows › Health Care › Beta Bionics (BBNX)
Beta Bionics (BBNX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 27, 2026 · Beta Bionics (BBNX) Q3 2026 earnings results →
Q3 2026 Revenue up 30% year over year to $35.5M · 69¢ of every $1 of revenue lost · operating margin -74.9%
Beta Bionics made $35.5M in Q3 2026 (+30% Y/Y). Operating margin -74.9%, net loss $24.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 27, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $35.5M in Q3 2026, up 30% year over year and up 11% from the previous quarter.
Gross margin was 57.3%, up 1.8 points from Q3 2025. Operating costs exceeded revenue by $26.6M, an operating margin of -74.9%. Operating expenses grew 46% against revenue growth of 30%. The fastest-growing cost line was Sales & marketing (+57%). The quarter ended with a net loss of $24.4M, wider than the previous quarter's $23.4M loss.
Operating cash flow was −$12.3M. Non-cash charges added back $892K of depreciation and $6.7M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $2.3M exceeded it, leaving free cash flow of −$14.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 27, 2026 | $35.5M | +30% | -74.9% | −$24.4M | −$12.3M |
| Q2 2026 | 10-Q | Jul 29, 2026 | $32.0M | +38% | -79.9% | −$23.4M | −$14.6M |
| Q1 2026 | 10-Q | Apr 21, 2026 | $27.6M | +57% | -87.9% | −$21.9M | −$23.8M |
| Q4 2025 | 10-K | Feb 24, 2026 | $32.1M | +57% | -50.2% | −$13.5M | −$8.6M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $27.3M | +63% | -62.5% | −$14.2M | −$8.7M |
| Q2 2025 | 10-Q | Jul 29, 2025 | $23.2M | +54% | -85.5% | −$16.9M | −$13.6M |
| Q1 2025 | 10-Q | May 6, 2025 | $17.6M | +36% | -105.7% | −$28.7M | −$20.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
In its own words, from its 8-K, filed Jul 29, 2026.
Beta Bionics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +30% against the peers' median +5%. Operating margin: -74.9% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BBNX Beta Bionics | Q3 2026 | $35.5M | +30% | -74.9% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Beta Bionics 10-Q on SEC EDGAR · CIK 1674632 · Surgical & Medical Instruments & Apparatus
13F: who owns BBNX and who is buying
More on BBNX
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results